US2011033496A1PendingUtilityA1

Vaccine for protection against lawsonia intracellulars

59
Assignee: JACOBS ANTONIUS ARNOLDUS CHRISTIAANPriority: Apr 18, 2008Filed: Apr 16, 2009Published: Feb 10, 2011
Est. expiryApr 18, 2028(~1.8 yrs left)· nominal 20-yr term from priority
Inventors:Antonius Arnoldus Christiaan JacobsPaul VermeijRuud Philip Antoon Maria SegersCarla Christina Schrier
A61P 37/04A61P 31/04A61P 31/12A61P 1/04A61P 1/12A61K 39/105A61K 2039/542A61K 2039/55566A61K 2039/552
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention pertains to the use of a non-live carbohydrate containing composition, the carbohydrate being also found in live Lawsonia intracellularis cells in association with the outer cell membrane of these cells, for the manufacture of a vaccine for protection against an infection with Lawsonia intracellularis, the vaccine being in a form suitable for systemic administration.

Claims

exact text as granted — not AI-modified
1 . A method of manufacturing a vaccine against  Lawsonia intracellularis  comprising admixing a non-live carbohydrate containing composition with a pharmaceutically acceptable carrier, wherein the non-live carbohydrate containing composition comprises a carbohydrate that also can be found in association with an outer cell membrane of a live  Lawsonia intracellularis  cell; and wherein the vaccine is in a form suitable for systemic administration. 
     
     
         2 . The method according to  claim 1 , characterised in that the carbohydrate containing composition is material resulting from the killing of  Lawsonia intracellularis  bacteria. 
     
     
         3 . The method according to  claim 2 , characterised in that the carbohydrate containing composition contains whole cells of killed  Lawsonia intracellularis  bacteria. 
     
     
         4 . The method according to  claim 3 , characterised in that the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         5 . The method according to  claim 4 , characterised in that the adjuvant comprises droplets of biodegradable oil and droplets of mineral oil, the droplets of biodegradable oil having an average size that differs from the average size of the droplets of mineral oil. 
     
     
         6 . The method according to  claim 5 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         7 . A non-live carbohydrate containing composition comprising a carbohydrate that also can be found in association with an outer cell membrane of a live  Lawsonia intracellularis  cell; wherein said composition is for use in the manufacture of a vaccine for protection against an infection with  Lawsonia intracellularis,  and wherein the vaccine is in a form suitable for systemic administration. 
     
     
         8 . The non-live carbohydrate containing composition of  claim 7  that comprises whole cells of killed  Lawsonia intracellularis  bacteria. 
     
     
         9 . A vaccine comprising the non-live carbohydrate containing composition of  claim 8 , and an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         10 . The vaccine of  claim 9  further comprising antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         11 . The method according to  claim 2  characterised in that the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         12 . The method according to  claim 1  characterised in that the vaccine comprises an oil in water adjuvant containing oil droplets of sub-micrometer size. 
     
     
         13 . The method according to  claim 11 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         14 . The method according to  claim 10 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         15 . The method according to  claim 6 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         16 . The method according to  claim 5 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         17 . The method according to  claim 4 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         18 . The method according to  claim 3 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         19 . The method according to  claim 2 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus. 
     
     
         20 . The method according to  claim 1 , characterised in that the vaccine further comprises antigens of  Mycoplasma hyopneumoniae  and Porcine circo virus.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.